Iterative Health

Iterative Health is a healthcare technology and services company focused on accelerating clinical research. It operates a multispecialty clinical research site network that embeds trials into community care settings, with therapeutic focus on gastroenterology, hepatology, obesity and cardiology. The company combines centralized trial operations, expert staffing, proprietary AI technology and clinical trial expertise to support research sites and to give sponsors and contract research organizations access to sites and patient populations.

For provider organizations, Iterative Health builds, optimizes and scales research ancillaries, supplying business operations (finance, budgets, legal support, reporting), trial performance support (study start-up, regulatory management, patient enrollment), sponsor and CRO communication, and research staff hiring, training and management. Training offerings include annual two-day retreats for principal investigators and clinical research coordinators, the on-demand "Iterative University" learning modules (some eligible for ACRP and SOCRA continuing education), and recurring virtual trainings and webinars. For sponsors and CROs, the company positions its network around site selection, activation speed and enrollment performance.

The company was previously known as Iterative Scopes, under which name it received FDA clearance in September 2022 for SKOUT, an AI-assisted polyp detection device. It maintains a research publication program, with articles in the Journal of Crohn's and Colitis, Gastroenterology (AGA Journals) and BMJ Journals, and presentations at ECCO, DDW and ACG meetings.

Founding story

Iterative Health was founded in 2017 by Jonathan Ng, MBBS, with the stated aim of addressing gaps in healthcare delivery so patients receive treatments sooner. Ng is a physician who holds an MBBS from the National University of Singapore and an MBA from MIT Sloan, and previously co-founded Optimimed, a venture to share MRI resources across Singapore hospitals.

Business model

Iterative Health acts as a site-centered clinical research organization, partnering with provider groups to establish and run research ancillaries while contracting with pharmaceutical, biotech, medical device and contract research organizations for study placement. It differentiates its model from traditional CROs and site management organizations by focusing on the profitability and operational efficiency of partner sites, which it supports with centralized operations, staffing, training and AI tooling.

The company sources and contracts study opportunities through an in-house trial partnership team and states that it secures premium rate cards for sites in its network, positioning research as a profitable ancillary service for partner provider organizations.

Traction

As of April 2026 the global network included more than 100 research sites across North America, Europe, India and Australia and partnerships with more than 40 pharmaceutical, biotech, medical device and CRO organizations. Against industry benchmarks for IBD trials, the company reports 2x faster site activation — reducing startup timelines by up to three months — and 3x higher patient enrollment rates, with more than two IBD patients randomized per business day across the network. Company materials also cite a 3.4x increase in patient enrollments and a 40% uplift in randomizations from AI pre-screening. It presented expanded trial performance data at Digestive Disease Week 2026 and network model validation data at ECCO 2026.

Latest developments

In April 2026 Iterative Health closed a $77 million Series C led by Intrepid Growth Partners and GV (Google Ventures), with new investors EDBI and a family office and participation from existing investors including Insight Partners and Obvious Ventures; Ajay Agrawal of Intrepid joined the board and Anthony Philippakis of GV joined as a board observer. The proceeds are earmarked for expansion beyond gastroenterology and hepatology into cardiology and obesity and for further geographic growth. Subsequent activity included the May 2026 acquisition of cardiology sites from NextStage Clinical Research, a July 2026 partnership with Gastroenterology Associates of New Jersey, and the August 2026 appointment of Dr. Samin K. Sharma as Honorary Chair of Interventional Cardiology.